Search

Selecting the first antipsychotic agent for the acute phase of a first episode of psychosis (FEP) is a critical task that may impact on the long-term outcome. Despite that, there is a lack of research comparing head-to-head different second-generation antipsychotics at this stage. The aim of this study was to compare the effectiveness of aripiprazole and risperidone in the treatment of the acute phase after a FEP. For that purpose, from February 2011 to October 2018, a prospective, randomized, open-label study was undertaken. Two hundred-sixty-six first-episode, drug-naïve patients were randomly assigned to aripiprazole (n = 136), or risperidone (n = 130) and followed-up for 6-weeks. The primary effectiveness measure was all-cause treatment discontinuation. In addition, an analysis based on intention-to-treat principle was conducted to assess clinical efficacy. The overall dropout rate at 6-week reached 19.5%. Effectiveness measures were similar between both treatment groups as treatment discontinuation rates (χ2 = 1.863; p = 0.172) and mean time until all-cause discontinuation (log rank = 1.421; p = 0.233) showed no statistically significant differences. In terms of clinical efficacy, risperidone proved a statistically significant better performance according to BPRS mean change between baseline and 6-week total score (t = 3.187; p = 0.002). Patients under risperidone treatment were significantly more likely to suffer sex-related adverse events. In conclusion, no differences regarding effectiveness were found between aripiprazole and risperidone for the acute-phase treatment of FEP. Despite the importance of efficacy during this phase of treatment, selecting the most effective treatment for the long-term outcome, requires addressing safety and patient´s preferences., Competing Interests: Declaration of Competing Interest Dr. Gómez-Revuelta, Dr. Pelayo-Terán, Dr. Vázquez-Bourgon, Dr. Mayoral-van-Son, Dr. Ayesa Arriola, and Mr. Ortiz-García de la Foz, report no conflicts of interest. Prof. Crespo-Facorro has received unrestricted research funding from Instituto de Salud Carlos III, MINECO, Gobierno de Cantabria, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), from the 7th European Union Framework Program and Lundbeck. He has also re- ceived honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Johnson & Johnson, Lundbeck, and Otsuka Pharmaceuticals., (Copyright © 2021 Elsevier B.V. and ECNP. All rights reserved.)

Schizophrenia is a severe brain disorder with an excess morbidity and mortality partly due to a higher incidence of metabolic disturbances and cardio-vascular events. The exposure to antipsychotic treatment has been observed linked to these metabolic abnormalities. This study explores the metabolic effects of aripiprazol, quetiapine and ziprasidone in drug-naïve patients with a first-episode of psychosis, at long-term. Two-hundred and two patients with first-episode of psychosis were included in the study. Patients were randomly assigned to receive quetiapine, ziprasidone, or aripiprazole. Clinical, sociodemographic and anthropometric measures, as well as lipid and glyceamic parameters, were recorded at baseline and after three years of initiating antipsychotic treatment. Body weight and BMI increased significantly after 3 years of follow-up (F = 35.0, p<0.001; and F = 37.6, p<0.001, respectively). Most of the increase in weight occurred within the first year of treatment. The proportion of patients meeting criteria for obesity (5.6% vs 25.7%; p<0.001), hypercholesterolemia (23.2% vs 41.7%; p<0.001) and hypertriglyceridemia (5.8% vs 23.0%; p<0.001) increased significantly. Head-to-head comparisons between antipsychotic groups revealed that the ziprasidone group presented significantly smaller increments in weight (p = 0.034) and BMI (p = 0.020) than aripiprazole group. After 3 years of having presented a first episode of psychosis, patients show significant increments in body weight and BMI, as well as in lipid and glycaemic parameters leading to clinical metabolic disturbances. In this context, the first year is the critical period for weight gain and development of metabolic changes. In this study, ziprasidone produced smaller weight gain than aripiprazole., (Copyright © 2020 Elsevier B.V. and ECNP. All rights reserved.)

We analyzed the impact of municipal areas socio-economic environment and trends in inequalities in smoking in Spain, 1987-2001. Inequalities in smoking have increased in both sexes. In males are the result of a higher decrease in the prevalence of smoking among the most advantaged groups, and in women, it is due to a higher increase among the less advantaged groups. Males residing in more deprived areas have a higher likelihood of smoking. For women, the likelihood of smoking is higher when residing in less deprived municipal areas up to 1995/1997. Individual and environmental social factors are relevant for smoking in Spain.

Determination of an effective rate constant and activation energy allowed the application of steady-state theory to predict concentrations of compound A from sevoflurane concentrations, fresh gas flow rate, absorbent temperature and amount of absorbent. Studies by eight research groups were compared. Lower concentrations of compound A than predicted were observed at low flow rates, suggesting that its degradation by the absorbent is important in limiting the maximum observed concentrations in closed and low-flow breathing systems. Trial-to-trial and batch-to-batch variations in compound A concentrations were observed in model system tests of commercial and pilot-plant absorbents. Chemical modification of the absorbent with glycerol lowered concentrations of compound A, possibly by formation of a nucleophilic addition product. An ideal chemical scavenger would remain stable and non-volatile in the absorbent before irreversibly reacting with compound A to form a stable non-volatile product.